QCM
CRNX icon

Quantinno Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Quantinno Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
33,734
+24,878
+281% +$1.11M ﹤0.01% 1989
2025
Q4 		$412K Buy
8,856
+1,049
+13% +$46.7K ﹤0.01% 2610
2025
Q3 		$325K Buy
7,807
+507
+7% +$16.2K ﹤0.01% 2396
2025
Q2 		$210K Buy
+7,300
New +$225K ﹤0.01% 2326

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Quantinno Capital Management's CRNX Position: Q1 2026 in Review

Quantinno Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 281% in Q1 2026, buying an estimated $1.11M and bringing the position to 33,734 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Quantinno Capital Management first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Quantinno Capital Management held 33,734 shares of Crinetics Pharmaceuticals worth $1.23M as of Q1 2026.
  • Quantinno Capital Management bought 24,878 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #1989 holding.
  • Quantinno Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.